Nouscom Stock

Nouscom are a biotech company working to develop a series of new, potent immunotherapeutics capable of selectively killing tumor cells.

Sign up today and learn more about Nouscom Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Nouscom Stock

Nouscom are a well established team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos, and are veterans in the field of oncolytic and genetic vaccines. The company is headquartered in Basel, Switzerland and has operations in Rome, Italy. The NousCom team is lead by experienced enterpreneurs that worked together for many years in previous successful enterprises, such as Okairos, under the leadership of Prof. Riccardo Cortese, who conceived the ideas behind those companies.

Funding History

May 2016$12.0M
November 2017$42.0M
November 2023$67.5M

Management

CEO

Marina Udier

Senior Director of regulatory affairs & Co- Founder

Cinzia Traboni

CMO

Patricia Delaite

Chief Scientific Officer & Co-Founder

Elisa Scarduelli

Board of Directors

Scott M. Rocklage

MD & Chairman

Göran Ando

Board Member

Sofia Ioannidou

Chief Operating Officer

Richard Davis

Board Member

Hakan Goker

Board Member

Thibaut Roulon

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo